Nonclinical Safety Assessment of PER977: A Small Molecule Reversal Agent for New Oral Anticoagulants and Heparins

International Journal of Toxicology

Volumn 34, Issue 4, 2015, Pages 308-317

  Sullivan, Dexter W ^a   Gad, Shayne C ^a   Laulicht, Bryan ^b   Bakhru, Sasha ^b   Steiner, Solomon ^b  

^a Gad Consulting Services   (United States)

^b Perosphere Inc   (United States)

Author keywords

anticoagulant; BAP; drug; NOAC; PER977; reversal agent

Indexed keywords

1,4 BIS(3 AMINOPROPYL)PIPERAZINE; CIRAPARANTAG; DRUG METABOLITE; UNCLASSIFIED DRUG; 1,4-BIS(3-AMINOPROPYL)PIPERAZINE; ARGININE; HEPARIN ANTAGONIST; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEAGLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG SAFETY; FEMALE; GENOTOXICITY; MALE; MAXIMUM TOLERATED DOSE; NERVOUS SYSTEM FUNCTION; NONHUMAN; RAT; RESPIRATORY FUNCTION; TOXICOKINETICS; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; ANIMAL; DNA DAMAGE; DOG; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; NO-OBSERVED-ADVERSE-EFFECT LEVEL; ORAL DRUG ADMINISTRATION; PRECLINICAL STUDY; SPRAGUE DAWLEY RAT; TOXICITY TESTING;

CANIS FAMILIARIS; RATTUS;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; ARGININE; DNA DAMAGE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPARIN ANTAGONISTS; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; TOXICITY TESTS;

EID: 84938687146     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581815590667     Document Type: Article

References (11)

1. Centers for Disease Control and Prevention. Venous Thromboembolism: A Public Health Concern. Web site. http://www.cdc.gov/NCBDDD/dvt/data.html. Accessed December 22, 2014.
2. Centers for Disease Control and Prevention. Number, Rate and Standard Error of all Listed Surgical and Nonsurgical Procedures for Discharges From Short-Stayhospitals by Selected Procedure Categories: United States, 2010. Web site. http://www.cdc.gov/nchs/data/nhds/4procedures/2010pro4-numberrate.pdf. Accessed December 22, 2014.
3. Centers for Disease Control and Prevention. Atrial Fibriallation Fact Sheet. Web site. http://www.cdc.gov/dhdsp/data-statistics/fact-sheets/docs/fs-atrial-fibrillation.pdf. Accessed January 13, 2014.
4. MacLean S, Mulla S, Akl EA,., Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (suppl 2): e1S-e23S.
5. Laulicht BE, Bakhru SH, Jiang X,. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Presented at: 24th Congress of the International Society on Thrombosis and Haematosis, June 29-July 4, 2013; Amsterm. Abstract. Web site. http://www.eventure-online.com/eventure/publicAbstractView.do?id=226718&congressId=6839. Accessed December 22, 2014.
6. Laulicht BE, Bakhru SH, Lee C,. Small molecule antidote for anticoagulants. Circulation. 2012; 126 (suppl 21): A11395. Abstract.
7. Bregman CL, Adler RR, Morton DG, Regan KS, Yano BL, Society of Toxicologic Pathology. Recommended tissue list for histopathologic examination in repeat-dose toxicity and carcinogenicity studies: a proposal of the Society of Toxicologic Pathology (STP). Toxicol Pathol. 2003; 31 (2): 252-253.
8. Sellers RS, Morton D, Michael B,. Society of Toxicologic Pathology position paper: organ weight recommendations for toxicology studies. Toxicol Pathol. 2007; 35 (5): 751-755.
9. Irwin S,. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia. 1968; 13 (3): 222-257.
10. International Conference on Harmonisation of Technical Requirements for Registartion of Pharmaceuticals for Human Use (ICH). ICH M3(R2) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals; 2009. Web site. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Multidisciplinary/M3-R2/Step4/M3-R2-Guideline.pdf. Accessed December 22, 2014.
11. Ansell JE, Bakhru SH, Laulicht BE,. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014; 371 (22): 2141-2142.